左西孟旦治疗急性失代偿性心力衰竭患者的短期疗效和安全性观察

doi:10.3969/j.issn.1006-6233.2023.10.027

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1203 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:分析研究急性失代偿性心力衰竭(ADHF)住院患者使用常规药物联合左西孟旦治疗方案在短期疗程内取得的效果及临床安全性。方法:选取2018年7月至2022年7月安徽医科大学第二附属医院收治的160例ADHF患者为研究对象,根据是否使用左西孟旦分为对照组和实验组,每组各80例,对照组给予常规药物治疗,实验组给予左西孟旦联合常规药物治疗。收集受试者入院时和治疗后1周左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、N末端脑利钠肽前体(N-terminal pro-B-type natriuretic peptide,NT-proBNP)、心肌肌钙蛋白I(cardiac troponin I,cTnI)数值及心功能分级,并进行临床疗效评价。结果:经药物治疗后,两组患者LVEF均升高,LVEDD均缩小,NT-proBNP.cTnI水平均下降,数据差异有意义(P<0.05)。两组治疗后对比,实验组LVEF升高、LVEDD缩小、NT-proBNP下降、cTnI下降幅度均优于对照组(P<0.05)。两组临床疗效对比差异无意义(P>0.05)。结论:急性失代偿性心力衰竭住院患者给予左西孟旦联合常规药物治疗能改善心肌功能相关指标,减缓患者临床病症,且安全有效。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	胡乐义
	周姝
	程景林
	刘泽岩

关键词 ：急性失代偿性心力衰竭, 左西孟旦, 左心室射血分数, 疗效

Abstract：Objective: To analyze and study the results and clinical safety of a treatment regimen of conventional drugs combined with levosimendan in hospitalized patients with acute decompensated heart failure (ADHF) over a short course of treatment. Methods: A total of 160 patients with ADHF admitted to the Second Affiliated Hospital of Anhui Medical University from July 2018 to July 2022 were selected and divided into control group with conventional medication and experimental group with levosimendan combined with conventional medication, 80 cases in each group. Left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD) , N-terminal pro-B-type natriuretic peptide(NT-proBNP) , cardiac troponin I (cTnI), and cardiac functional grading were collected at admission and one week after treatment. At the same time, the therapeutic effect was analyzed and evaluated. Results: After treatment, LVEF levels of all subjects increased( both P<0.05 ). There were a significant decrease in the level of LVEDD、NT-proBNP、cTnI for both groups compared with those before treatment( both P<0.05 ). After the treatment of levosimendan, the magnitude of changes in LVEF, LVEDD, NT-proBNP and cTnI of the patients in the experimental group was better than that in the control group, and the difference between the two groups was significant (all P<0.05). Conclusion: Levosimendan in combination with conventional drugs improves myocardial function and slows down clinical symptoms in hospitalized patients with acute decompensated heart failure, and is safe and effective.

Key words： Acute decompensated heart failure Levosimendan Left ventricular ejection fraction Efficacy

基金资助:安徽医科大学青年科学基金,(编号:2021xkj286)

引用本文:

胡乐义, 周姝, 程景林, 刘泽岩. 左西孟旦治疗急性失代偿性心力衰竭患者的短期疗效和安全性观察[J]. 河北医学, 2023, 29(10): 1725-1730.
HU Leyi, ZHOU Shu, CHENG Jinglin, et al. Short-Term Efficacy and Safety of Levosimendan in the Treatment of Patients with Acute Decompensated Heart Failure. HeBei Med, 2023, 29(10): 1725-1730.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.10.027 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I10/1725

[1] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[2] Yandraoalli S,Tariq S,Aronow WS.Advances in chemical pharmacotherapy for managing acute decompensated heart failure[J].Expert Opin Pharmacother,2017,18(5):1-5.
[3] Packer M,Colucci W,Fisher L,et al.Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure[J].JACC Heart Fail,2013,1(2):103-111.
[4] 贾志,郭牧,张丽媛,等.左西孟旦与米力农治疗心力衰竭的疗效比较[J].中华急诊医学杂志,2014,23(7):740-745.
[5] Fukushima A,Kinugawa S.Renin-Angiotensin-Aldosterone system and natriuretic peptides as possible targets of waon therapy in heart failure[J].Circ,2017,81(5):635-636.
[6] McDonagh TA,Metra M,Adamo M,et al.2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart,2021,42(36):3599-3726.
[7] Bavendiek U,Berliner D,Davila LA,et al.Rationale and design of the DIGIT-HF trial (digitoxin to Improve outcomes in patients with advanced chronic heart failure):a randomized,double-blind,placebo-controlled study[J].Eur Heart Fail,2019,21(5):676-684.
[8] Papp Z,Agostoni P,Alvarez J,et al.Levosimendan efficacy and safety:20 years of SIMDAX in clinical use[J].Cardiovasc Pharmacol,2020,76(1):4-22.
[9] Comin CJ,Manito N,Sergovia CJ,et al.Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure:the LION-HEART multicentre randomised trial[J].Eur Heart Fail,2018,20(7):1128-1136.
[10] Polzl G,Allipour BS,Comin CJ,et al.Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period[J].ESC Heart Fail,2019,6(1):174-181.
[11] Tycinska A,Gierlotka M,Bartus S,et al.Repetitive use of LEvosimendan in ambulatory heart failure patients (LEIA-HF) - The rationale and study design[J].Adv Med Sci,2022,67(1):18-22.
[12] 陈运龙,黄岚,刘小燕,等.左西孟旦治疗扩张型心肌病急性失代偿心力衰竭住院患者的短期疗效及安全性观察[J].中华心力衰竭和心肌病杂志,2020,4(4):256-260.
[13] 付文科,孙玉发,郝卫军,等.左西孟旦治疗老年缺血性心肌病所致急性失代偿性心力衰竭的疗效和安全性分析[J].中华老年性脑血管杂志,2017,19(2):153-155.
[14] 彭艳玲,王冉冉,黄洁,等.左西孟旦治疗慢性心力衰竭的疗效分析[J].中国急救复苏与灾害医学杂志,2018,13(6):533-535.
[15] Martin J,Ana AP,Antonio LP,et al.Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients:the LAICA study[J].ESC Heart Failure,2021,8(6):4820-4831.